The CARESS consortium consisting of 3 RTD performers (CNR, ICO, LABOR) and 4 SME's (IRBM, ODPM, OPTO, AMEDA) combines comprehensive research capabilities and scientific competences with long-term experience in manufacturing and commercialization.
The complimentary skills of the consortium members and their commit-ment to the project aim are a solid basis to ensure that the project output
will provide the intended contribution to an improvement of cancer therapy for the sake of patients all around the world.
A detailed project management plan has been set up defining different work packages specifying the tasks of each consortium member and defining communication structures to ensure efficient collabroation of the consortium members from different parts of Europe.
Consiglio Nazionale delle Ricerche
The Consiglio Nazionale delle Ricerche (CNR) is the largest public research institution in Italy, the only one under the Research Ministry performing multidisciplinary activities. The goal is to perform research, to promote innovation and competitiveness of the national industrial system, to promote the internationalization of the national research system, to provide technologies and solutions to emerging public and private needs.
CNR is organized in 11 Departments and 108 Institutes. Departments are organizational units, structured by macro – areas of technological and scientific research. The Institutes, located throughout Italy, have the task of proposing plans and implementing the scheduled activities, coordinated by the Departments. Each Institute is affiliated to one Department but is not dependent on the Department for what concerns its scientific research and duties. The geographical distribution of the Institutes, and their interdisciplinary and multidisciplinary features, enable them to contribute to the growth of regional innovation systems.
The Institute of Metodologie Chimiche, (IMC) directly involved in this project, is affiliated to the Department of Molecular Design (DPM). The general goal of DPM is the development, through the "chemical manufacturing", of innovative functionalities in molecular, macromolecular and solid systems with different level of structural organization. The purpose is to contribute to the innovation in some specific fields such as the development of new molecules with bio-pharmaceutical properties, products and industrial processes with low environmental impact, materials built-up from innovative nanostructures. The Department strategy is focused in three main areas of interest: health, sustainability and convergent technologies
Institut de Cancérologie de l'ouest Paul Papin (ICO)
ICO was created in January 2011 by merger of the Centres for the Fight Against Cancer Paul Papin and René Gauducheau. It is a bi-site institute with ICO Paul Papin in Angers and Nantes ICO René Gauducheau so as to offer patients close support while positioning itself as a center of regional and national excellence.
ICO is one of 19 Centres for the Fight Against Cancer, a nationwide group founded in 1945. The "Hospital, Patients, Health and Territories" Act in July 2009 placed the Centres for the Fight Against Cancer in the category of Private Health Facilities Collective Interest (ESPIC), which are nonprofit entities providing public service hospital missions in the field of oncology.
Clinical services, medical technology and research laboratories are organized for a multidisciplinary and comprehension activity. Surgeons, radiotherapists, chemotherapists, radiologists, pathologists, biologists, chemists and biophysicists participating in the diagnosis, treatment and monitoring, are involved in a close and continuing cooperation in the interests of effective management of patients.
Click to watch a presentation of Institut de Cancérologie de l'ouest Paul Papin.
LABOR is an industrial research laboratory with the mission to carry out R&D activities and projects in close cooperation with industry and public research bodies, establishing with them long term research and cooperation agreements.
The company is conceived so as to offer a lean and agile counterpart both to its industrial clients and research organizations, acting "downstream" to the latter ones, for the finalization and customization of basic research towards the requirements of the industrial environment. At this scope, LABOR offers the competence of a number of professionals, creating a fertile and flexible environment aimed to the development of highly innovative projects.
The staff involved acquired extensive experience in the pool of professional consultants and experts who have developed a long standing and consolidated knowledge in the assessment and exploitation of advanced technologies and professional project management in research projects.
The core competencies of the company are allocated into 3 departments:
1. Renewable Energy Sources
2. Microelectronics and automation
3. Industrial and Process Chemistry
The company currently operates in Rome (TECNOPOLO TIBURTINO).
The infrastructure includes a laboratory for electronics and automation, a test area for hydrogen technologies; a laboratory specialized in industrial chemistry, a lab dedicated to renewable energies.
IRBM Science Park S.p.a.
IRBM Science Park was created in October 2009 as a spin-off of Merck Research Laboratories. The built area includes laboratories, conference rooms and a state of the art laboratory animal research facility. IRBM Science Park Scientists have discovered hundreds of lead molecules with more than 25 product candidates advancing into preclinical and clinical development.
One of these molecules became the first in class HIV integrase inhibitor Isentress™ for the treatment of HIV AIDS patients. A second molecule currently in Phase II clinical trials is MK-5172 known as Grazoprevir for the HCV therapy. Several key inventors of the Isentress™ and Grazoprevir discovery teams are among the scientists of IRBM Science Park. The contributions of IRBM Science Park Scientists to these achievements are documented in over 800 papers and 100 patents.
IRBM Science Park provides a broad spectrum of drug discovery services ranging from lead identification, through lead optimization and the generation of preclinical drug candidates, modalities including small molecules, peptides, and vaccines. The search for new drugs demands far-reaching and highly specific skills and technologies. The adoption of multidisciplinary approaches that employ state-of-the art infrastructure is crucial in efficiently and cost-effectively advancing drug discovery efforts.
The Company is actively pursuing R&D programs focused on rare and neglected diseases some examples are Thalassemia, Sickle Cell Anaemia, Malaria and other parasitic diseases and rare cancer. Furthermore in 2010 IRBM created a Public Private Consortium with CNR and ISS called CNCCS (www.cnccs.it), whose main mission is to create a national screening centre and a national centre for rare and neglected disease.
Onco Drug Personalized Medicine (ODPM)
ODPM develops innovative high-performance solutions for personalized medicine in the field of oncology. Our team has created a revolutionary approach to prevent serious toxicities (inclusing death) in first exposures to fluoropyrimidines and to personalize protocols for optimized treatment efficiency.
ODPM currently markets two web-based services to independent and hospital-based laboratories as well as oncologists to help determine dosages in all patients treated with fluoropyrimidines.
ODPM Tox™ predicts and evaluates the risk of toxicity in patients to be treated with fluoropyrimidines (all 5-FU protocols, capecitabine, UFT, S1, etc) using genotyping, phenotyping combined with other specific patient characteristics. This innovative and exclusive system promotes a better quality of life for the patient during the chemotherapy and significant cost reduction for hospitals due to the reduction (if not complete elimination) of toxicity-related emergency care.
ODPM Protocol™ offers guidance and therapeutic monitoring for oncologists in order to optimize the efficiency 5-FU (FOLFOX, FOLFIRI, etc) treatments by adapting each dosage according to patients’ personal parameters and relevant chemotherapy protocol.
Our overarching objectives are as follows:
> to avoid severe toxic reactions and death related to fluoropyrimidines
> to enhance treatment efficiency
> to provide better quality of life for patients and improve overall survival rate
> to diminish costs related to treatment of toxicities
Optomesures is an innovative French company (official innovative status from the French Ministry of Research ) created in 2005 with the objective to develop, manufacture and sell measuring and analysis systems. First involved in the food and agro industry and more specifically in the wine industry with its successful MICROLAB™ , small and very cost effective oenological laboratory, a new development for water is ongoing, especially in the field of on-line quality assessment. The philosophy of Optomesures is to provide small companies with sophisticated instruments not available up to now thanks to a very aggressive price politics. OPTOMESURES has also collaborations with engineering schools and laboratories in Toulouse, allowing up to date developments focused on real customer needs.
AMEDA Labordiagnostik GmbH
AMEDA is a manufacturer specialized in supply of modern and reliable technology for use in in-vitro diagnostics. The product portfolio known worldwide under the AMP Diagnostics brand includes instrumentation and diagnostic kits in various convenient configurations covering the segments of clinical chemistry, immunology, hematology and coagulation, as well as urine and rapid diagnostics.
The commitment to highest quality standards and the continuous development of the product portfolio as well as flexibility in meeting customer requirements are a solid and reliable basis for long-term collaboration with highly qualified and well established distribution partners in more than 60 countries of Europe, the Middle East, Asia, Africa and South America.
The team of AMEDA maintains long-term experience in working with in-vitro diagnostic instrumentation in respect to both sales and marketing, as well as maintenance and technical support. Developing new products the aspects of reliability, accuracy and user convenience are always emphasized.
Consiglio Nazionale delle Ricerche
Institut de Cancérologie de l'ouest Paul Papin
IRBM Science Park S.p.a.
Onco Drug Personalized Medicine
Saint Marcel Paulel, France
AMEDA Labordiagnostik GmbH
The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7/2007-2013), managed by the REA - Research Executive Agency under the Grant Agreement n° 315398